|
Mechanisms Of Disease Progression in Aortic Stenosis - the MODAS Study
RECRUITINGSponsored by Heinrich-Heine University, Duesseldorf
Actively Recruiting
SponsorHeinrich-Heine University, Duesseldorf
Started2023-07-01
Est. completion2026-07
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT05851209
Summary
Biomarkers and mechanisms in the progression of aortic valve stenosis are sometimes not sufficiently understood. The current project will take into account image morphological and immunological aspects that predict the development of hemodynamically relevant aortic valve stenosis in order to identify high-risk patients and to develop further therapeutic options.
Eligibility
Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria: * The patient has an acquired (tricuspid) moderate aortic valve stenosis, which is the reason for regular outpatient cardiological care. * The subject has been informed verbally and in writing about the study and has given written consent to participate in this study. * Age \> 18 years Exclusion Criteria: * The subject has contraindications for the performance of a magnetic resonance imaging or computed tomography (e.g., severe arrhythmias , contrast agent intolerance, a pacemaker, or severe renal insufficiency or severe renal insufficiency or claustrophobia). * Presence of only mild or already high-grade acquired tricuspid Aortic valve stenosis * Patient with bicuspid aortic valve * Inability to follow the instructions of study personnel * Lack of written informed consent
Conditions7
Aortic StenosisAortic Valve CalcificationDisease ProgressionGeneticsHeart DiseaseImagingPathogenesis
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
SponsorHeinrich-Heine University, Duesseldorf
Started2023-07-01
Est. completion2026-07
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT05851209